KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial.
Heikki JoensuuEva WardelmannMikael ErikssonAnnette ReichardtKirsten Sundby HallJochen SchütteSilke CameronPeter HohenbergerHarri Jaakko SihtoPhilipp J JostLars Hartwin LindnerSebastian BauerBengt NilssonRaija KallioTommi PesonenPeter ReichardtPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Compared to 1 year of imatinib, 3 years of adjuvant imatinib led to 66% reduction in the estimated risk of death and a high 10-year OS rate in the subset of patients with a KIT exon 11 deletion/indel mutation.
Keyphrases